Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Abstract: Described herein are biodegradable plant pots comprising an additive such as polyvinyl alcohol (PVA), polyvinyl acetate (PVAC), lime, a wax emulsion, or a combination thereof. The additives may be incorporated into the biodegradable plant pots during production, or impregnated into an additive-free biodegradable plant pot. Also described herein are methods and kits for making a biodegradable plant pot.

Abstract: A plant growth media composition, articles made therefrom, and methods of making and using the same are described. The plant growth media composition includes a combination of one or more plant growth substrate materials and an additive such as cellulose fibers, clay, carrageenan, alginate, chitosan, or combinations thereof.

Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Abstract: Systems, methods, and kits for plant propagation are disclosed. In some embodiments, the systems, methods, and kits for plant propagation involve a plug, a wrap, and a container. The container is configured to house the plug with a plant growing therein, where the plug is encircled by the wrap within the container, and where the plug and the wrap may include the same material.

Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Abstract: A plant growth media composition, articles made therefrom, and methods of making and using the same are described. The plant growth media composition includes a combination of one or more plant growth substrate materials and an additive such as cellulose fibers, clay, carrageenan, alginate, chitosan, or combinations thereof.

Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Abstract: Described herein are biodegradable plant pots comprising an additive such as polyvinyl alcohol (PVA), polyvinyl acetate (PVAC), lime, a wax emulsion, or a combination thereof. The additives may be incorporated into the biodegradable plant pots during production, or impregnated into an additive-free biodegradable plant pot. Also described herein are methods and kits for making a biodegradable plant pot.

Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Abstract: A plant material naturally containing protection and/or sustenance compounds (hereinafter referred to as “fortification compounds”) that provide beneficial and/or improved properties when mixed with a growing medium, supporting a rooting system, is ground up and added to a substrate mix. The ground plant material may be mixed with cold or heated water and/or chemical treated to extract the organic fortification compound(s) there from. The fortified substrate mix may be used as a substrate or may be added to or compose molded or pressed horticulture materials such as plant pots, plant containers, plant trays, polyurethane plant plugs, peat bags, and plant pellets, as examples.

Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.